Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer

International Journal of Clinical Oncology

Volumn 5, Issue 1, 2000, Pages 18-21

  Yamada, Yasuhide ^a   Aiba, Keisuke ^b   Horikosi, Noboru ^b   Hanai, Masaaki ^b   Uno, Shinji ^b   Osawa, Hiroshi ^b   Mizunuma, Nobuyuki ^b   Takahashi, Shyunji ^b   Ito, Yoshinori ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Anthracycline resistant; Breast cancer; Cisplatin; Low dose FP

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; METASTASIS; NAUSEA; PRIORITY JOURNAL;

EID: 0034026230     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470050004     Document Type: Article

References (15)

1. MacMillan WE, Wobery WH, Welling PG (1978) Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 38:3479-3482
2. Schackney SE (1985) Cell kinetics and cancer chemotherapy. In: Calabresi P, Schein PS, Rosenberg SA (eds) Medical oncology. McMillan, New York, pp 41-60
3. Tsujinaka T, Kido Y, Shiozaki H, et al. (1992) Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. Cancer 70:2761-2765
4. Lokich JJ, Ahlgren JD, Gullo JJ, et al. (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 17:425-432
5. Sledge GW, Loehler PJ, Roth BJ, Einhorn LH (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814
6. Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108-112
7. Yap HY, Salem P, Hortobagyi GN, et al. (1978) Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer. Cancer Treat Rep 62:405-408
8. Shirasaka T, Shimamoto Y, Ohshima H, et al. (1993) Metabolic basis of the synergistic antitumor activites of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32:167-172
9. Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923-8925
10. Chung YS, Yamashita Y, Inoue T, et al. (1997) Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma, Cancer 80:1-7
11. Sasaki K, Hirata K, Denno R, et al. (1997) Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma (in Japanese). Jpn J Cancer Chemother 24:959-964
12. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting of results of cancer treatment. Cancer 47:207-214
13. Ray-Coquard I, Biron P, Bachelot T, et al. (1988) Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and paclitaxel-containing regimens. Cancer 82:134-140
14. Weber BL, Vogel C, Jones S, et al. (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730
15. Valero V, Holmes FA, Walters RS, et al. (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894